Advertisement

Drugs & Therapy Perspectives

, Volume 35, Issue 9, pp 459–459 | Cite as

Correction to: Caplacizumab in acquired thrombotic thrombocytopenic purpura: a profile of its use

  • Hannah A. Blair
  • Katherine A. Lyseng-WilliamsonEmail author
Open Access
Correction
  • 151 Downloads

Correction to: Drugs & Therapy Perspectives (2019) 35:263–270  https://doi.org/10.1007/s40267-019-00632-w

The article Caplacizumab in acquired thrombotic thrombocytopenic purpura: a profile of its use, written by Hannah A. Blair and Katherine A. Lyseng-Williamson, was originally published Online First without open access. After publication in volume 35, issue 6, pages 263–270, Ablynx, a Sanofi Company requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Ablynx, a Sanofi Company. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article has been corrected.

Copyright information

© Springer Nature 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations